Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism

• Drug: PF-04171327
  
  25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
• Drug: PF-04171327
  
  25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
• Drug: Prednisone
  
  5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
• Drug: PF-04171327
  
  3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
• Drug: PF-04171327
  
  10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
• Drug: Prednisone
  
  5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

• Experimental: (Part 1) 25 mg PF-04171327 predosed at -8 hours prior to OGTT
  
  Intervention: Drug: PF-04171327
• Experimental: (Part 1) 25 mg PF-04171327 predosed at -12 hours prior to OGTT
  
  Intervention: Drug: PF-04171327
• Active Comparator: (Part 1) 5 mg Prednisone
  
  5 mg prednisone tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
  Intervention: Drug: Prednisone
• Experimental: (Part 2) 3 mg PF-04171327
  
  Intervention: Drug: PF-04171327
• Experimental: (Part 2) 10 mg PF-04171327
  
  Intervention: Drug: PF-04171327
• Active Comparator: (Part 2) 5 mg Prednisone
  
  Intervention: Drug: Prednisone
• Active Comparator: (Part 2) 20 mg Prednisone
  
  Intervention: Drug: Prednisone

Inclusion Criteria:

• BMI 17.5 to 30.5 kg/m2 and total body weight >50 kg

Exclusion Criteria:

• Fasting glucose above the limits of the reference range for healthy individuals
• "No treatment" Oral Glucose Tolerance Test (OGTT) indicative of impaired fasting glucose or impaired glucose tolerance
• Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation